High-dose risankizumab produced rapid response in patients with psoriasis, with some patients maintaining that response over an extended period, Medscape reports.

The report centers on the interleukin-23 inhibitor risankizumab, which is already established in the treatment of moderate to severe plaque psoriasis at its approved dose. The new findings address a higher-dose regimen, which delivered faster skin clearance than clinicians typically see with standard dosing. According to the report, the effect appeared quickly, and a portion of patients retained their response even after treatment was stopped or extended, suggesting durability in a defined subgroup.

Medscape's coverage frames the results as relevant to dermatologists managing psoriasis patients who need rapid onset of action — for example, those with high disease burden or specific quality-of-life demands — and to those interested in whether intensified induction dosing can change the durability of remission. The report does not present the high-dose regimen as an approved option; it remains an investigational or off-label consideration until further data and regulatory review are complete.

The standard approach to psoriasis pharmacotherapy has shifted decisively toward IL-23 inhibitors over the past decade, and risankizumab has been a key part of that shift. Its mechanism — selective blockade of the p19 subunit of IL-23 — underpins both its efficacy in clearing psoriatic plaques and its relatively favorable maintenance schedule. The new high-dose data extend that profile by testing whether more drug front-loaded into treatment can accelerate the timeline to clear or almost clear skin.

Clinicians reading the Medscape report will note the practical question it raises: if a subset of patients can achieve durable response after high-dose induction, could treatment intervals be lengthened or treatment be paused in those patients? That question sits at the center of current psoriasis management debates, where guidelines and payers increasingly push toward treat-to-target strategies and optimized discontinuation protocols.

The report does not claim universal durability. It specifies that some patients maintained response, implying heterogeneity in the cohort — a pattern familiar from other biologic discontinuation studies in psoriasis, where relapse timelines vary widely by drug class and patient characteristics. Dermatologists will want to see the full trial data — including PASI response rates, dosing intervals, and follow-up duration — before drawing conclusions about which patients are the best candidates for a high-dose strategy.

For now, the Medscape report positions high-dose risankizumab as a signal worth watching: rapid response confirmed, durability demonstrated in a subset, and full characterization still pending. Peer-reviewed publication of the complete dataset will determine whether the regimen moves from an investigational finding into routine practice discussion.